Видео ютуба по тегу Medicines: Dasatinib

Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients
Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients
Dasatinib vs imatinib in the treatment of paediatric ALL
Dasatinib vs imatinib in the treatment of paediatric ALL
Dasatinib-blinatumomab for adult Ph+ ALL
Dasatinib-blinatumomab for adult Ph+ ALL
Comparing dasatinib-blinatumomab vs ponatinib-blinatumomab in newly diagnosed Ph+ B-ALL
Comparing dasatinib-blinatumomab vs ponatinib-blinatumomab in newly diagnosed Ph+ B-ALL
Dasatinib-blinatumomab for ALL
Dasatinib-blinatumomab for ALL
Dasatinib vs imatinib for paediatric Ph+ALL
Dasatinib vs imatinib for paediatric Ph+ALL
Generic Cancer Drugs: The Hope and Hidden Challenges
Generic Cancer Drugs: The Hope and Hidden Challenges
Effects of dasatinib on xenograft lung tumour models with YES1 overexpression
Effects of dasatinib on xenograft lung tumour models with YES1 overexpression
SWOG 1318: dasatinib plus blinatumomab in the treatment of older patients with B-ALL
SWOG 1318: dasatinib plus blinatumomab in the treatment of older patients with B-ALL
Asciminib plus dasatinib for the treatment of Ph+ B-ALL: insights from a Phase I trial
Asciminib plus dasatinib for the treatment of Ph+ B-ALL: insights from a Phase I trial
What are the efficacy and safety considerations of dasatinib therapy?
What are the efficacy and safety considerations of dasatinib therapy?
Update on dasitinib from DASISION and SPIRIT2 trials for CML
Update on dasitinib from DASISION and SPIRIT2 trials for CML
Dual ABL1 inhibition in elderly ALL: asciminib, dasatinib, prednisone
Dual ABL1 inhibition in elderly ALL: asciminib, dasatinib, prednisone
Dasatinib in the Second-Line Setting
Dasatinib in the Second-Line Setting
Sprycel (dasatinib) - Drug Rx Information
Sprycel (dasatinib) - Drug Rx Information
D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph+ ALL
D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph+ ALL
Final analysis of the GIMEMA LAL2116 (D-ALBA) trial: dasatinib + blinatumomab in Ph+ B-ALL
Final analysis of the GIMEMA LAL2116 (D-ALBA) trial: dasatinib + blinatumomab in Ph+ B-ALL
Nonalcoholic fatty liver disease is worsened by dasatinib and quercetin
Nonalcoholic fatty liver disease is worsened by dasatinib and quercetin